Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
51 studies found for:    ARSENIC ACID
Show Display Options
Rank Status Study
21 Unknown  Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
Condition: Carcinoma, Hepatocellular
Interventions: Drug: TACE containing As2O3;   Drug: TACE containing placebo
22 Recruiting Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Realgar-Indigo naturalis formula;   Drug: all-trans retinoic acid;   Drug: Arsenic trioxide;   Drug: Hydroxyurea
23 Terminated
Has Results
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: idarubicin;   Drug: tretinoin
24 Recruiting Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Conditions: Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Childhood Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
Interventions: Drug: Arsenic Trioxide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Questionnaire Administration;   Drug: Tretinoin
25 Recruiting Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Condition: Leukemia
Interventions: Drug: ATRA;   Drug: ATO;   Drug: GO (Gemtuzumab ozogamicin);   Drug: Methylprednisolone
26 Recruiting The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization
Conditions: Ischemic Heart Disease;   Myocardial Ischemia;   Coronary Disease;   Acute Coronary Syndrome
Intervention: Device: AVI® Arsenic trioxide drug eluting stent
27 Recruiting Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
Condition: AML
Interventions: Drug: Cytarabine;   Drug: all-trans retinoic acid;   Drug: Arsenic Trioxide
28 Completed Arsenic Trioxide in Treating Patients With Urothelial Cancer
Conditions: Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Transitional Cell Carcinoma of the Bladder;   Ureter Cancer
Intervention: Drug: arsenic trioxide
29 Terminated Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
Conditions: Adenocarcinoma of the Esophagus;   Stage III Esophageal Cancer;   Stage IV Esophageal Cancer
Intervention: Drug: arsenic trioxide
30 Completed
Has Results
Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
Conditions: Basal Cell Carcinoma of the Skin;   Recurrent Skin Cancer
Intervention: Drug: arsenic trioxide
31 Withdrawn Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: arsenic trioxide;   Other: laboratory biomarker analysis
32 Terminated Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: arsenic trioxide;   Other: laboratory biomarker analysis
33 Recruiting Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Condition: Leukemia
Intervention: Drug: Ara-c
34 Active, not recruiting Phase III Trial in Acute Promyelocytic Leukemia Patients
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: all-trans retinoic acid;   Drug: all-trans retinoic acid (ATRA)
35 Recruiting Selenium and Arsenic Pharmacodynamics
Condition: Arsenic Poisoning Chronic
Interventions: Dietary Supplement: Anhydrous selenite;   Dietary Supplement: Sodium chloride
36 Completed Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: arsenic trioxide;   Radiation: radiation therapy
37 Terminated Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
Condition: Metastatic Melanoma
Interventions: Drug: Disulfiram;   Drug: Arsenic trioxide
38 Completed Selenium in the Treatment of Arsenic Toxicity and Cancers
Conditions: Arsenical Melanosis;   Arsenical Keratosis;   Arsenical Cancers;   Arsenicosis;   Arsenic Exposure;   Arsenic Toxicity;   Arsenic Poisoning
Interventions: Drug: sodium selenite;   Drug: placebo
39 Not yet recruiting Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
Condition: Skin Basal Cell Carcinoma
Interventions: Drug: Arsenic Trioxide;   Drug: Itraconazole;   Other: Laboratory Biomarker Analysis
40 Completed Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pamidronate disodium;   Drug: arsenic trioxide;   Other: laboratory biomarker analysis;   Other: pharmacological study

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-51) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.